Your browser doesn't support javascript.
loading
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.
Ramachandran, Preethi; Perisetti, Abhilash; Gajendran, Mahesh; Jean-Louis, Farla; Bansal, Pardeep; Dwivedi, Alok Kumar; Goyal, Hemant.
Afiliación
  • Ramachandran P; Midamerica Cancer Care, West Kansas City, Missouri.
  • Perisetti A; Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Gajendran M; Texas Tech University, Paul L Foster School of Medicine, El Paso, Texas.
  • Jean-Louis F; Department of Internal Medicine, Brookdale University Hospital and Medical Center, Brooklyn, New York.
  • Bansal P; Division of Gastroenterology, Moses Taylor Hospital and Reginal Hospital of Scranton, Scranton, Pennsylvania.
  • Dwivedi AK; Division of Biostatistics and Epidemiology, Department of Molecular and Translational Medicine, Texas Tech University, Paul L Foster School of Medicine, El Paso, Texas.
  • Goyal H; The Wright Center for Graduate Medical Education, Scranton, Pennsylvania, USA.
Eur J Gastroenterol Hepatol ; 34(2): 137-141, 2022 02 01.
Article en En | MEDLINE | ID: mdl-33252418
ABSTRACT

INTRODUCTION:

Severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors (PPIs), which could predispose the patients to severe COVID-19.

METHODS:

We studied the association between prehospitalization PPI exposure and clinical outcomes among hospitalized COVID-19 patients.

RESULTS:

A total of 295 hospitalized COVID-19 patients were included in the study. 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.3 times higher risk of acute respiratory distress syndrome after adjusting for confounding variables.

CONCLUSION:

We found that prehospitalization PPI-exposure is independently associated with worse clinical outcomes, including mortality in COVID-19 patients, regardless of the presence of cardiovascular comorbidities.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de la Bomba de Protones / COVID-19 Límite: Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de la Bomba de Protones / COVID-19 Límite: Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article